Assenagon Asset Management S.A. Takes Position in AtriCure, Inc. $ATRC

Assenagon Asset Management S.A. bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 62,334 shares of the medical device company’s stock, valued at approximately $1,744,000.

A number of other large investors have also recently bought and sold shares of ATRC. Oak Harvest Investment Services bought a new stake in shares of AtriCure in the 4th quarter valued at about $1,484,000. F m Investments LLC bought a new stake in AtriCure in the 4th quarter valued at about $2,872,000. Vanguard Group Inc. grew its position in shares of AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of AtriCure during the 1st quarter valued at about $7,922,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of AtriCure by 8.2% during the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock valued at $28,466,000 after purchasing an additional 75,862 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Performance

Shares of ATRC opened at $44.30 on Friday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The company’s 50 day simple moving average is $33.91 and its 200-day simple moving average is $31.52. The firm has a market cap of $2.25 billion, a PE ratio of 210.96 and a beta of 1.20. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $44.48.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Buying and Selling

In related news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the sale, the director directly owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 47,246 shares of company stock valued at $1,777,845. Company insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ATRC shares. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Raymond James Financial set a $52.00 price objective on AtriCure in a research report on Tuesday, July 21st. UBS Group lowered their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.